| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer
1 company
See Tai Sandi serves as a Chief Development Officer at LXEO. Across recent SEC filings that breaks down to 0 buys and 6 sells. Those positions are worth an estimated $607K at current prices.
Historically, See Tai Sandi's trades have earned a below-average insider score of 32/100 across 5 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -48.8%.
The biggest single holding is LXEO (~$607K) as Chief Development Officer. The recent filings there lean toward selling, a net 6,509 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | LXEO Lexeo Therapeutics, Inc. | Chief Development Officer | Sell | 386 | $9.27 | $3,578.22 | -0.6% | -31.6% | - | |
| Oct 17, 2025 | LXEO Lexeo Therapeutics, Inc. | Chief Development Officer | Sell | 3,888 | $8.94 | $34,766.82 | -5.6% | -21.7% | - | |
| Aug 18, 2025 | LXEO Lexeo Therapeutics, Inc. | Chief Development Officer | Sell | 382 | $4.67 | $1,783.18 | -0.6% | +92.7% | - | |
| May 16, 2025 | LXEO Lexeo Therapeutics, Inc. | Chief Development Officer | Sell | 367 | $2.77 | $1,018.06 | -0.6% | +47.8% | +57.1% | |
| Feb 19, 2025 | LXEO Lexeo Therapeutics, Inc. | Chief Development Officer | Sell | 1,486 | $4.41 | $6,557.72 | -2.7% | -20.9% | +40.6% |